Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours

Trial Profile

An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Paclitaxel (Primary) ; XP 105 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 20 Mar 2019 Results presented in a Xynomic Pharmaceuticals media release.
    • 20 Mar 2019 According to a Xynomic Pharmaceuticals media release, Filippo G. De Braud, at Fondazione IRCCS Istituto Nazionale dei Tumori, is a lead investigator of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top